Miśkiewicz-Bujna Justyna, Miśkiewicz-Migoń Izabella, Szmit Zofia, Przystupski Dawid, Rosa Monika, Król Anna, Kałwak Krzysztof, Ussowicz Marek, Gorczyńska Ewa
Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland.
Department of Paediatric Anaesthesiology and Intensive Care, Wroclaw Medical University, Wroclaw, Poland.
Front Pediatr. 2022 Aug 22;10:956108. doi: 10.3389/fped.2022.956108. eCollection 2022.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a treatment method for a wide range of malignant and non-malignant diseases. Infants constitute a distinct patient group, especially due to their organ immaturity and differences in drug metabolism. The present paper aims to analyse the short- and long-term outcomes after allo-HSCT in infants.
In the study period, 67 patients under 12 months of age underwent allo-HSCT. This study is a retrospective analysis of patient medical records, in the form of paper and electronic documentation.
The probability of 5-year OS was 69% and 72% in patients with malignant and non-malignant diseases, respectively. The allo-HSCT from a matched donor was associated with improved OS in comparison to haploidentical donor (0.8 vs. 0.58%, = 0.0425). The overall incidence of acute graft-vs.-host disease (aGVHD) was 59.3%, and grade III-IV aGVHD was diagnosed in 23% of patients. The 100-day non-relapse mortality (NRM) in the study cohort was 17.9%, while the 5-year NRM was 26.9%. Among the causes of NRM, infections occurred in 83.3% of patients, and aGVHD in 16.3% of individuals. Twenty-two children (32.8%) required hospitalization in the pediatric intensive care unit (PICU). The median length of PICU hospitalization was 6 days (range 1 to 12 days). Late sequelae diagnosed during post-transplant surveillance included ocular disorders in 26.8% of patients, cardiac complications in 4.4%, as well as endocrinopathy with short stature (<3rd percentile) in 37.2% and overt hypothyroidism in 35.4%. In the long-term perspective, 83.3% of survivors were able to attend a regular school.
Improvements in unrelated donor availability, and better supportive care resulted in better outcomes. Management of infant allo-HSCT recipients requires the formation of multi-disciplinary specialist teams. In addition, the role of parental empowerment must be acknowledged; for example, in speech therapy and rehabilitation.
异基因造血干细胞移植(allo-HSCT)是治疗多种恶性和非恶性疾病的一种方法。婴儿是一个独特的患者群体,尤其是因为他们的器官不成熟以及药物代谢存在差异。本文旨在分析婴儿allo-HSCT后的短期和长期结果。
在研究期间,67名12个月以下的患者接受了allo-HSCT。本研究是以纸质和电子文档形式对患者病历进行的回顾性分析。
恶性疾病和非恶性疾病患者的5年总生存率(OS)分别为69%和72%。与单倍体相合供体相比,来自匹配供体的allo-HSCT与更高的OS相关(0.8对0.58%,P = 0.0425)。急性移植物抗宿主病(aGVHD)的总体发生率为59.3%,23%的患者被诊断为III-IV级aGVHD。研究队列中的100天非复发死亡率(NRM)为17.9%,而5年NRM为26.9%。在NRM的原因中,83.3%的患者发生感染,16.3%的患者发生aGVHD。22名儿童(32.8%)需要入住儿科重症监护病房(PICU)。PICU住院的中位时长为6天(范围1至12天)。移植后监测期间诊断出的晚期后遗症包括26.8%的患者出现眼部疾病,4.4%的患者出现心脏并发症,37.2%的患者出现身材矮小(低于第3百分位数)的内分泌病,35.4%的患者出现明显的甲状腺功能减退。从长期来看,83.3%的幸存者能够正常上学。
无关供体可及性的改善以及更好的支持性护理带来了更好的结果。婴儿allo-HSCT受者的管理需要组建多学科专家团队。此外,必须认识到家长赋能的作用;例如,在言语治疗和康复方面。